Dopaminergic Axons: Key Recitalists in Parkinson’s Disease
- 12 October 2021
- journal article
- review article
- Published by Springer Nature in Neurochemical Research
- Vol. 47 (2) , 234-248
Abstract
Parkinson's disease (PD) is associated with dopamine depletion in the striatum owing to the selective and progressive loss of the nigrostriatal dopaminergic neurons, which results in motor dysfunction and secondary clinical manifestations. The dopamine level in the striatum is preserved because of the innervation of the substantia nigra (SN) dopaminergic neurons into it. Therefore, protection of the SN neurons is crucial for maintaining the dopamine level in the striatum and for ensuring the desired motor coordination. Several strategies have been devised to protect the degenerating dopaminergic neurons or to restore the dopamine levels for treating PD. Most of the methods focus exclusively on preventing cell body death in the neurons. Although advances have been made in understanding the disease, the search for disease-modifying drugs is an ongoing process. The present review describes the evidence from studies involving patients with PD as well as PD models that axon terminals are highly vulnerable to exogenous and endogenous insults and degenerate at the early stage of the disease. Impairment of mitochondrial dynamics, Ca2+ homeostasis, axonal transport, and loss of plasticity of axon terminals appear before the neuronal degeneration in PD. Furthermore, distortion of synaptic morphology and reduction of postsynaptic dendritic spines are the neuropathological hallmarks of early-stage disease. Thus, the review proposes a shift in focus from discerning the mechanism of neuronal cell body loss and targeting it to an entirely different approach of preventing axonal degeneration. The review also suggests appropriate strategies to prevent the loss of synaptic terminals, which could induce regrowth of the axon and its auxiliary fibers and might offer relief from the symptomatic features of PD.Keywords
This publication has 136 references indexed in Scilit:
- Chronic overload of SEPT4, a parkin substrate that aggregates in Parkinson’s disease, causes behavioral alterations but not neurodegeneration in miceMolecular Brain, 2013
- The prion hypothesis in Parkinson's disease: Braak to the futureActa Neuropathologica Communications, 2013
- Living on the edge with too many mouths to feed: Why dopamine neurons dieMovement Disorders, 2012
- Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's DiseaseAntioxidants & Redox Signaling, 2012
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's diseaseNeuroscience, 2011
- How Addictive Drugs Disrupt Presynaptic Dopamine NeurotransmissionNeuron, 2011
- SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s diseaseBrain, 2010
- Clinical progression in Parkinson disease and the neurobiology of axonsAnnals of Neurology, 2010
- Parkinson's disease mutations in PINK1 result in decreased Complex I activity and deficient synaptic functionEMBO Molecular Medicine, 2009
- 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase CProceedings of the National Academy of Sciences, 2007